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DNA repair and synthetic lethality 
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Tumors often have DNA repair defects, suggesting additional inhibition of other DNA repair pathways in 
tumors may lead to synthetic lethality. Accumulating data demonstrate that DNA repair-defective tumors, in 
particular homologous recombination (HR), are highly sensitive to DNA-damaging agents. Thus, HR-defective 
tumors exhibit potential vulnerability to the synthetic lethality approach, which may lead to new therapeutic 
strategies. It is well known that poly (adenosine diphosphate (ADP)-ribose) polymerase (PARP) inhibitors show 
the synthetically lethal effect in tumors defective in BRCA1 or BRCA2 genes encoded proteins that are required 
for efficient HR. In this review, we summarize the strategies of targeting DNA repair pathways and other DNA 
metabolic functions to cause synthetic lethality in HR-defective tumor cells. 
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  Synthetic lethality is defined as a genetic combination 
of mutations in two or more genes that leads to cell 
death, whereas a mutation in any one of the genes does 
not [1]. This phenomenon was first discovered from the 
investigation of fruit flies in 1922. Since the identical 
consequence was also found in another species, Dros- 
phila pseudoobscura, the concept of “synthetic lethality” 
was established. In addition, it would be called synthetic 
sick when a genetic combination of mutations doesn’t 
cause deadly damage; however, these combinations are 
often categorized together with synthetic lethal interac- 
tions [1-2].  
The concept of synthetic lethality in the DNA damage 
response has recently grown in popularity with the fin- 
ding that poly (adenosine diphosphate (ADP)-ribose) 
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polymerase (PARP) inhibitors are specifically toxic to 
homologous recombination (HR)-defective cells [3-4]. 
Playing a key role in maintaining genetic stability, HR is 
a major repair pathway for double-strand breaks (DSBs) 
utilizing undamaged homologous DNA sequence [5-6]. 
In this review, we summarize the strategies of targeting 
DNA repair pathways and other DNA metabolic func- 
tions to cause synthetic lethality in HR-defective tumor 
cells, with the hope that they result in tumor-cell specific 
cancer therapy. 
 
Targeting a specific DNA repair pathway for syn- 
thetic lethality  
 
There are multiple pathways of DNA repair, which 
can partially compensate for each other [5]. Apart from 
HR, non-homologous end joining (NHEJ) is the major 
alternative DSB repair mechanism. NHEJ modifies the 
broken DNA ends prior to ligation, resulting in a 
mutagenic change at the break site [6]. Nucleotide and 
base excision repair plus DNA mismatch repair are also 
important repair pathways in response to DNA damage 
affecting a single strand of DNA, where the undamaged 
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strand is used as the template for repair [7]. Cancer cells 
often have DNA repair defects, suggesting additional 
inhibition of other DNA repair pathway in cancer cells 
may achieve synthetic lethality. For HR-defective tumors, 
which may be more prevalent than was first thought, 
there are a number of new avenues for developing 
cancer therapy, which exploit the concept of synthetic 
lethality, and which are currently being tested in clinical 
trials [6]. 
Inhibition of PARP, a key element for base excision 
repair pathway, can have synthetic lethality in tumors with 
defective breast cancer susceptibility genes (BRCA1, 
BRCA2), which are required for efficient HR repair 
[3-4]. The PARP protein has the ability to bind single- 
strand breaks (SSBs) and facilitate SSBs repair [8]. 
Inhibition of PARP protein can result in persistent SSBs, 
perhaps with the PARP protein attached to the SSB and 
preventing alternative pathways of SSB repair [9]. Once 
the replication fork encounters an SSB, the lesion can be 
converted into a DSB requiring for HR for repair. This 
type of DSB will not be repaired in HR-defective cells. 
NHEJ may not be an effective alternative pathway for 
this special type of one-ended DSB that occurs during 
DNA replication. If PARP inhibitors are present, the 
number of open SSB is increased, resulting in a greater 
likelihood of replication-associated DSB, which in turn 
will produce chromatid breaks and exchanges, resulting 
in cell death. Several PARP inhibitors have now been 
used in clinical trials for the treatment of breast and 
ovarian cancer [6]. 
Cells with defective HR are vulnerable to synthetic 
lethality if other DNA repair mechanisms in the HR- 
defective cells are inhibited. The DNA repair protein 
Rad52 plays a key role in the HR of Saccharomyces 
cerevisiae [10]. However, knockout of the Rad52 gene in 
vertebrates results in mild phenotypes, without obvious 
defects in HR, suggesting that Rad52 may be redundant 
for HR in higher eukaryotes [11-12]. Our recent publi- 
cation has indicated there are two, probably independent, 
pathways of Rad51-dependent HR in mammalian cells 
[13]: the Rad52 pathway, which is the only pathway of 
HR in yeast cells, and the BRCA2 pathway, which is 
found extensively in the animal and plant kingdoms. Many 
species have both pathways of repair, but some have 
only Rad52 (such as yeast) and some have only BRCA2 
(such as Drosophila melanogaster and Caenorhabditis 
elegans). The role of Rad52 in the repair of DSB by HR 
and in overcoming DNA-replication fork stalling is mas- 
ked when BRCA2 is present. Rad52 mediates Rad51- 
dependent repair and is an alternative HR pathway that 
is independent of BRCA2. There are potentially lethal 
effects of inactivating Rad52 in BRCA2-deficient cells 
that could provide another new specific treatment resul- 
ting in the synthetic lethality of a subset of breast 
cancers. 
Germline mutations in BRCA1 or BRCA2 gene result 
in a cumulative lifetime risk of developing hereditary 
breast and ovarian cancer. However, the mutations of 
BRCA gene in sporadic breast cancers are not frequently 
examined, and it has been determined that both BRCA1 
mRNA and protein expression are significantly down- 
regulated in sporadic breast cancer and ovarian cancer 
cases [14]. Increasing evidence suggests that the BRCA 
and Fanconi anemia (FA) pathways may be inactivated by 
multiple mechanisms in a substantial proportion of spo- 
radic breast cancers, and that these cancers could be effec- 
tively BRCA-deficient, which has been called “BRCA- 
ness” [15]. These non-mutational mechanisms of BRCA- 
deficiency in sporadic breast cancer and ovarian cancer 
are still unclear. Our unpublished data indicate that 
BRCA1 and BRCA2 work in the same HR repair path- 
way, and that BRCA2 protein expression is regulated by 
functional BRCA1. These observations suggest that non- 
functional BRCA1 will lead to BRCA2 protein instability, 
resulting in additional BRCA2-mediated HR repair path- 
way defects. These data raise the question of whether the 
inhibition of Rad52-mediated HR pathway would be syn- 
thetically lethal in tumors with down-regulated BRCA1 
or BRCA2 protein expression. This hypothesis would 
expand the potential number of tumors that can be 
targeted using a synthetic lethality strategy for BRCA- 
deficient tumors and Rad52. The working model of 
BRCA-Rad52 and synthetic lethality is shown in Figure 1. 
 
Targeting genes regulating cell cycle checkpoints for 
synthetic lethality  
 
In response to DNA damage, both DNA repair and 
cell cycle checkpoint pathways will be activated. Acti- 
vation of checkpoints prevents the progression of cells to 
the next phase of the cycle allowing time for repair of 
the damaged DNA. The synthetic lethality strategy for 
cancer therapy is that inhibiting cell cycle checkpoints 
will result the accumulation of damaged DNA in cells 
with pre-existing checkpoint or repair defects. The tumor 
suppressor p53 is required for controlling the G1/S 
checkpoint and is frequently inactivated in human cancer 
cells, especially in BRCA1- or BRCA2-associated tumors 
(unpublished results) [16]. Thus, targeting the checkpoint 
proteins required for S- and G2 in HR-defective cells is a 
potential strategy for killing cancer cells [17]. The ataxia 
telangiectasia mutated (ATM)-related kinase (ATR)-cell 
cycle checkpoint kinase 1 (Chk1) pathway is responsible 
for controlling S- and G2 phase checkpoint in response 
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to DNA damage [6]. It has been demonstrated that Chk1 
inhibitors are able to sensitize p53 mutant human cells 
[17-18] and FA-mediated repair pathway deficient tumors 
[19], as several Chk1 inhibitors were used for a phase 
ĉ/Ċ clinical trial. Apart from the inhibition of Chk1, the 
inhibition of another G2 checkpoint kinase, WEE1, dis- 
played higher cytotoxicity to p53-deficient cells [20]. 
Inhibition of the ATM kinase, which also functions in 
cell cycle checkpoints, leads to the radiosensitization of 




















Figure 1 Schematic representation of the synthetic lethality of BRCA-Rad52 
 
 
The ATR-induced S phase cell cycle checkpoint sup- 
presses both the formation of recombination foci and the 
recombinational repair of DSBs at chromosome breaks 
[22]. Chk1 plays a key role in signaling to protect cells 
against lethal DNA lesions, perhaps in part by regulating 
HR [23]. Many cancer cells have lost the protection 
against DNA damage afforded by the p53 protein, so the 
repair-defective cancer cells will often have minimal 
protection against DNA damage persisting well into the 
S-phase of the cell cycle [24]. The ATR-Chk1 pathway 
is therefore the only protection remaining in the cancer 
cells against the effects of DNA damage: targeting this 
pathway has the potential for significant therapeutic gain 
in the checkpoint and repair defective cancer cells. How- 
ever, the precise relationship between cell cycle check- 
point proteins and the BRCA-pathway, and the mecha- 
nism of how it regulates HR, is poorly understood. 
Targeting cell cycle checkpoint proteins in DNA repair- 
defective tumors is an additional strategy of synthetic 
lethality in cancer therapy. 
                 
Targeting DNA replication 
 
Double-stranded DNA lesions produced at replication 
forks are substrates for HR repair [5]. DNA-damaging 
agents that interfere with DNA replication are employed 
for the treatment of HR-defective tumors. DNA repli- 
cation processes that are targeted by chemotherapeutic 
drugs include antimetabolites, topoisomerase poisons, 
DNA cross-linking agents, and hydroxyurea (HU) [6, 
25]. The initial rationale for their use was the selective 
targeting of rapidly dividing cancer cells. The DNA 
lesions induced by these DNA-damaging agents cannot 
be efficiently repaired in HR-defective cells. For example, 
HU can deplete the cells of dNTPs, which results in 
stalled replication forks, which then collapse to form 
DNA DSB. Current data [25] indicates that the phos- 
phorylated replication protein A2 (RPA2)-p plays an 
important role in linking replication arrest to HR, and 
RPA2-p-defective cells are hypersensitive to HU treat- 
ment. Targeting DNA replication in DNA repair-defective 
cells could also be a viable synthetic lethality strategy in 
cancer cells. 
In summary, synthetic lethality approaches to thera- 
peutic interventions in DNA repair defect-cancer cells 
involves a number of DNA metabolic processes, inclu- 
ding DNA replication, cell cycle checkpoints, and other 
DNA repair pathways. DNA repair defects can be found 
in hereditary as well as sporadic cancer. The extent of 
HR-defects in cancer cells needs to be determined by 
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new functional testing of human cancers. As a conse- 
quence, the new cancer-specific synthetic lethal strategies 
can be tested on a larger pool of patients than just 
BRCA-mutation carriers. More efficient and specific 
approaches may be discovered, which would provide new 
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